For MDS, the mechanism of action of TIM-3-targeted therapy may combine the advantages of “tumor cell inhibition” and “immune activation”, but more large-scale phase III trials are needed to validate the survival benefit, and it may become an alternative option for PD-1-resistant or highly immunosuppressive MDS in the future. The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.